|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 222.51 USD | -0.27% |
|
-0.41% | +25.75% |
| 12-08 | OSE Immunotherapeutics Amends Partnership With AbbVie for Inflammation Drug Development | MT |
| 12-08 | OSE Immunotherapeutics Amends Partnership Agreement with AbbVie on ABBV-230 |  |
| Capitalization | 394B 339B 318B 296B 545B 35,432B 593B 3,686B 1,433B 16,794B 1,480B 1,448B 61,876B | P/E ratio 2025 * |
52.1x | P/E ratio 2026 * | 22.9x |
|---|---|---|---|---|---|
| Enterprise value | 450B 387B 363B 338B 623B 40,465B 677B 4,210B 1,636B 19,180B 1,690B 1,654B 70,667B | EV / Sales 2025 * |
7.39x | EV / Sales 2026 * | 6.62x |
| Free-Float |
96.39% | Yield 2025 * |
2.92% | Yield 2026 * | 3.04% |
Last Transcript: AbbVie Inc.
| 1 day | -0.27% | ||
| 1 week | -0.41% | ||
| Current month | -1.87% | ||
| 1 month | +2.17% | ||
| 3 months | +6.19% | ||
| 6 months | +18.13% | ||
| Current year | +25.75% |
| 1 week | 220.23 |  | 230.94 |
| 1 month | 216.15 | | 239.29 |
| Current year | 164.39 | | 244.81 |
| 1 year | 164.39 | | 244.81 |
| 3 years | 130.96 | | 244.81 |
| 5 years | 101.55 | | 244.81 |
| 10 years | 50.71 | | 244.81 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 54 | 2024-06-30 |
Scott Reents
DFI | Director of Finance/CFO | 58 | 2022-06-22 |
Roopal Thakkar
CTO | Chief Tech/Sci/R&D Officer | - | 2002-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 64 | 2012-12-31 |
William Burnside
BRD | Director/Board Member | 73 | 2012-12-31 |
Edward Rapp
BRD | Director/Board Member | 67 | 2012-12-31 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 7.12% | 6 M€ | 0.00% | - |
| 6.85% | 26 M€ | +11.55% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.27% | -0.41% | +26.55% | +37.04% | 394B | |
| -1.65% | -6.10% | +22.25% | +172.13% | 893B | |
| -0.09% | -2.56% | +33.80% | +13.90% | 486B | |
| -0.76% | +2.04% | +22.68% | +4.08% | 336B | |
| +0.10% | -1.76% | +27.58% | +20.11% | 280B | |
| +0.17% | +2.46% | +18.94% | +25.23% | 253B | |
| -1.92% | -3.89% | -6.45% | -10.74% | 246B | |
| +0.07% | -4.85% | -61.91% | -33.31% | 207B | |
| -4.31% | -6.85% | +13.53% | +13.11% | 173B | |
| -1.55% | -3.66% | +31.77% | +35.69% | 150B | |
| Average | -0.97% | -2.03% | +12.87% | +27.72% | 341.87B | |
| Weighted average by Cap. | -0.90% | -2.41% | +17.45% | +54.59% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 60.93B 52.35B 49.11B 45.76B 84.28B 5,474B 91.59B 570B 221B 2,595B 229B 224B 9,560B | 66.62B 57.24B 53.7B 50.04B 92.15B 5,986B 100B 623B 242B 2,837B 250B 245B 10,453B |
| Net income | 9.1B 7.82B 7.33B 6.83B 12.58B 817B 13.68B 85.05B 33.05B 387B 34.14B 33.42B 1,428B | 17.43B 14.97B 14.05B 13.09B 24.11B 1,566B 26.2B 163B 63.32B 742B 65.4B 64.02B 2,735B |
| Net Debt | 56.02B 48.13B 45.16B 42.08B 77.49B 5,034B 84.21B 524B 204B 2,386B 210B 206B 8,791B | 46.47B 39.93B 37.46B 34.9B 64.28B 4,175B 69.86B 434B 169B 1,979B 174B 171B 7,292B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-09 | 223.44 $ | +0.14% | 2,544,913 |
| 25-12-08 | 223.12 $ | -1.31% | 4,006,095 |
| 25-12-05 | 226.08 $ | -1.15% | 3,985,199 |
| 25-12-04 | 228.71 $ | -0.66% | 3,733,100 |
| 25-12-03 | 230.24 $ | +2.62% | 4,873,263 |
Delayed Quote Nyse, December 09, 2025 at 03:53 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABBV Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition